Skip to main content

Bariatric Arterial Embolization Safe, Effective in Patients With Severe Obesity

Medically reviewed by Carmen Pope, BPharm. Last updated on April 2, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, April 2, 2024 -- Bariatric arterial embolization (BAE) is feasible, effective, and well tolerated among patients with severe obesity, according to a study presented at the annual meeting of the Society of Interventional Radiology, held from March 23 to 28 in Salt Lake City.

Adham Khalil, M.D., from Johns Hopkins University in Baltimore, and colleagues evaluated the safety and efficacy of BAE in patients with obesity using novel, customized, tightly calibrated 100 to 200 µm radiopaque embolic microspheres “BTG-001933” (Boston Scientific). The analysis included 10 adults (aged 21 to 70 years) with body mass index ≥35 kg/m2 and weight ≤400 lb.

The researchers reported that the left gastric artery (10) was embolized with or without the gastroepiploic artery (six) with a 100 percent technical success rate. There were no major adverse events, but minor adverse events included a healing mucosal ulcer at three-month endoscopy and a vascular access site pseudoaneurysm (unrelated). At baseline, three months, and six months, weight-to-muscle volume ratios were 10.3, 10.0, and 9.2 kg/L (Rrm = 0.89), respectively.

"BAE using tightly calibrated 100 to 200 µm radiopaque microspheres 'BTG-001933' is feasible and appears to be well tolerated by patients with severe obesity with weight loss outcomes demonstrating higher efficacy compared to other embolic agents used in previous studies," the authors write.

Abstract

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Most Slow Responders to Tirzepatide Do Lose Clinically Meaningful Weight

TUESDAY, May 14, 2024 -- Among slow responders to tirzepatide treatment at week 12, 90 percent went on to achieve clinically meaningful weight reduction (≥5 percent) by week...

Metabolic Syndrome, Obesity Independently Linked to Breast Cancer

MONDAY, May 13, 2024 -- Metabolic syndrome (MetS) and obesity have independent and distinct associations with breast cancer subtypes and mortality, according to a study published...

Bariatric Surgery Tied to Higher Short-Term Risk for Venous Thromboembolism

THURSDAY, May 9, 2024 -- In the short term, bariatric surgery is associated with a greater risk for venous thromboembolism (VTE), but in the long-term, it is associated with lower...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.